165 related articles for article (PubMed ID: 29079174)
21. Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Laios A; O'Toole S; Flavin R; Martin C; Kelly L; Ring M; Finn SP; Barrett C; Loda M; Gleeson N; D'Arcy T; McGuinness E; Sheils O; Sheppard B; O' Leary J
Mol Cancer; 2008 Apr; 7():35. PubMed ID: 18442408
[TBL] [Abstract][Full Text] [Related]
22. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
23. miR-7 expression in serous ovarian carcinomas.
Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
[TBL] [Abstract][Full Text] [Related]
24. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
[TBL] [Abstract][Full Text] [Related]
25. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
[TBL] [Abstract][Full Text] [Related]
26. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
27. [Effects of miR-135a on HOXA10 expression, proliferation and apoptosis of ovarian cancer cells].
Tang WW; Wan GP; Wan YC; Zhang L; Cheng WJ
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):364-9. PubMed ID: 24016480
[TBL] [Abstract][Full Text] [Related]
28. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis.
Shen J; Xiao Z; Wu WK; Wang MH; To KF; Chen Y; Yang W; Li MS; Shin VY; Tong JH; Kang W; Zhang L; Li M; Wang L; Lu L; Chan RL; Wong SH; Yu J; Chan MT; Chan FK; Sung JJ; Cheng AS; Cho CH
Cancer Res; 2015 Feb; 75(4):754-65. PubMed ID: 25503559
[TBL] [Abstract][Full Text] [Related]
30. Enhanced SMARCD1, a subunit of the SWI/SNF complex, promotes liver cancer growth through the mTOR pathway.
Zhou Y; Xu Q; Tao L; Chen Y; Shu Y; Wu Z; Lu C; Shi Y; Bu H
Clin Sci (Lond); 2020 Jun; 134(12):1457-1472. PubMed ID: 32514535
[TBL] [Abstract][Full Text] [Related]
31. miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1.
Tang H; Yao L; Tao X; Yu Y; Chen M; Zhang R; Xu C
Int J Mol Med; 2013 Aug; 32(2):381-8. PubMed ID: 23722670
[TBL] [Abstract][Full Text] [Related]
32. A microRNA survival signature (MiSS) for advanced ovarian cancer.
Shih KK; Qin LX; Tanner EJ; Zhou Q; Bisogna M; Dao F; Olvera N; Viale A; Barakat RR; Levine DA
Gynecol Oncol; 2011 Jun; 121(3):444-50. PubMed ID: 21354599
[TBL] [Abstract][Full Text] [Related]
33. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
34. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
35. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2.
Nakahara O; Takamori H; Iwatsuki M; Baba Y; Sakamoto Y; Tanaka H; Chikamoto A; Horino K; Beppu T; Kanemitsu K; Honda Y; Iyama K; Baba H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S565-71. PubMed ID: 21932133
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
37. Exosome-derived miRNAs and ovarian carcinoma progression.
Vaksman O; Tropé C; Davidson B; Reich R
Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
[TBL] [Abstract][Full Text] [Related]
38. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
Berkel C; Cacan E
Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
[TBL] [Abstract][Full Text] [Related]
40. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
